Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer?
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background Approximately 10% of patients with breast cancer who are treated with breast-conserving surgery (BCS) develop an ipsilateral-breast tumor recurrence (IBTR). The optimal local therapy for women with BRCA-associated breast carcinoma remains controversial. We report the outcome of BCS in BRCA mutation carriers followed at a single institution. Methods A total of 54 women with BRCA1/2-associated breast cancer treated with BCS and whole breast radiotherapy were matched for age, tumor size, and time of surgery with 162 patients with sporadic breast cancer who had the same treatment between February 1994 and October 2007. Primary end points were cumulative incidence of IBTR and contralateral breast cancer (CBC). Median follow-up was 4 years for both groups. Results Median age was 36 and 37 years for mutation carriers and controls, respectively; mean tumor size was 1.8 cm in carriers and 1.9 cm in controls. Ten-year cumulative incidence of IBTR was 27% for mutation carriers and 4% for sporadic controls (hazard ratio 3.9; 95% confidence interval 1.1-13.8; P = 0.03). Ten-year cumulative incidence of CBC was 25% for mutation carriers and 1% for sporadic controls (P = 0.03). Conclusions Our data suggest that IBTR risk after BCS in BRCA1/2 mutation carriers is increased compared with patients who have sporadic breast cancer. Likewise, the risk of CBC seems to be increased in this group. These risks and the likelihood of developing new primary tumors should be discussed with car…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Four studies including”
From Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers (2016) · cites this paper as [12]
In the citing paper
“Recently published new study of very young patients by Garcia-Etienne et al. [41] suggested after median follow-up of 4 years increased rates of ipsilateral breast cancer incidence in mutation carriers (9.3 vs. 2.5%) without complete information concerning the radiotherapy modalities (total dose, boost to the tumour bed) is given.”
From Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature (2010) · cites this paper as [41]
Citations
Cites
Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., Jeong, J.-H., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa022152 · Cited by 6,249
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., Aguilar, M., & Marubini, E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020989 · Cited by 4,450
Self-citationProphylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.188 · Cited by 1,171
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973
Efficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., Frost, M. H., Grant, C. S., Donohue, J. H., Woods, J. E., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.21.1633 · Cited by 743
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A., Snyder, C., Watson, P., Cannon-Albright, L., Isaacs, C., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 672
Research works printed but not linked: 1
- Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer. 1998; 83:310–9. · DOI · Paper page
Cited by
Molecular Subtypes and Local-Regional Control of Breast Cancer
Fragomeni, S. M., Sciallis, A., & Jeruss, J. S. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.08.005 · Cited by 450
Tung, N. M., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., Dragun, A., Gelpi, J. B., Hofstatter, E. W., Isaacs, C. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00299 · Cited by 332
Cardoso, F., Loibl, S., Pagani, O., Graziottin, A., Panizza, P., Martincich, L., Gentilini, O., Peccatori, F., Fourquet, A., Delaloge, S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.10.004 · Cited by 304
Self-citationPierce, L. J., Phillips, K.-A., Griffith, K. A., Buys, S., Gaffney, D. K., Moran, M. S., Haffty, B. G., Ben-David, M., Kaufman, B., Garber, J. E., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0894-z · Cited by 199
Valachis, A., Nearchou, A. D., & Lind, P. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2890-1 · Cited by 178
Metadata
- Authors
- Garcia-Etienne, C. A., Barile, M., Gentilini, O. D., Botteri, E., Rotmensz, N., Sagona, A., Farante, G., Galimberti, V., Luini, A., Veronesi, P., & Bonanni, B.
- Affiliations
- European Institute of Oncology (IT)
- ORCID
- Venue
- Annals of Surgical Oncology
- Published
- 2009-08-01
- Volume
- 16
- Issue
- 12
- Pages
- 3380-3387
- ISSN
- 1068-9265 (ISSN-L)
- 1534-4681
- OpenAlex
- W2092786953
- Cited by
- 100
- References
- 38
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 10 · 2019: 7 · 2018: 2 · 2017: 9 · 2016: 4 · 2015: 6 · 2014: 9 · 2013: 9 · 2012: 11
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Annals of Surgical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- breast-conserving surgery, BRCA1 mutation carriers, BRCA2 mutation carriers, hereditary breast cancer, ipsilateral breast tumor recurrence, contralateral breast cancer, whole breast irradiation, risk mitigation strategies
- MeSH terms
- Adult, Breast Neoplasms, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Prospective Studies, Retrospective Studies, Cohort Studies, Mastectomy, Segmental, Survival Rate, Case-Control Studies, Treatment Outcome, Germ-Line Mutation, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Genes, BRCA1, Genes, BRCA2, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer? https://app.cochat.ai/papers/10.1245/s10434-009-0638-7
- The paper
- Garcia-Etienne, C. A., Barile, M., Gentilini, O. D., Botteri, E., Rotmensz, N., Sagona, A., Farante, G., Galimberti, V., Luini, A., Veronesi, P., & Bonanni, B. (2009). Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer? Annals of Surgical Oncology. https://doi.org/10.1245/s10434-009-0638-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.